Sanofi
SNYHealthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
Follow SNY
Alert me
Where the cash went Twelve months to Sep 30, 2026
Free cash flow was $23.8B, and none of it went on dividends or buybacks. Cash rose by $6.7B. Lines the picture does not name came to −$17.1B. What is a cash flow statement?
- Free cash flow
- $23.8B 100.0% of operating cash flow
- Returned to shareholders
- $0.00 0.00% of free cash flow
- Debt, net
- $0.00 borrowed
- Change in cash
- +$6.7B over the period
| Operating cash flow | 23.8 |
|---|---|
| Free cash flow | 23.8 |
| Other | −17.1 |
| Change in cash | 6.7 |
| Q2 FY25 | Q4 FY25 | Q2 FY26 | |
|---|---|---|---|
| Operating cash flow | $15.4B | $26.0B | $21.6B |
| Capex | −$6.5B | −$7.4B | −$7.1B |
| Free cash flow | $8.8B | $18.6B | $14.5B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more TTM periods Free account |
5,587.98 | 5,587.98 | 4,505.89 | — |
Depreciation & Amortization |
13,880.14 | — | 15,672.60 | — | |
Non Cash Items (Other) |
(1,075.77) | — | (1,213.52) | — | |
Accounts Receivable Change |
(2,266.30) | — | (2,312.77) | — | |
Change in inventories |
(2,235.27) | — | (2,395.01) | — | |
Accounts Payable Change |
1,604.66 | — | 1,121.04 | — | |
Change in other assets and liabilities |
368.50 | — | 3,443.16 | — | |
Operating Cash Flow |
26,024.74 | — | 21,596.60 | 23,792.82 | |
Capital expenditures |
(7,417.62) | — | (7,054.14) | — | |
Net Aquisitions |
23,801.06 | — | 23,548.53 | — | |
Long-Term Investments Change (Net) |
(17,478.35) | — | (16,990.54) | — | |
Other investing activities |
(214.28) | — | (207.33) | — | |
Investing cash flow |
2,369.54 | — | 4,065.34 | 4,291.09 | |
Repayment/Issuance of Debt (Net) |
11,149.49 | — | 8,683.07 | — | |
Equity Repurchase (Common, Net) |
(10,429.02) | — | (11,278.65) | — | |
Dividends Paid (Total) |
(21,120.30) | — | (21,774.22) | — | |
Other financial activities |
(125.03) | — | — | — | |
Financing cash flow |
(20,617.45) | — | (18,255.43) | (21,866.43) | |
Exchange Rate Adjustment |
(114.92) | — | (78.76) | (59.07) | |
Discontinued Operations and Adjustments |
197.81 | — | — | — | |
Change in Cash |
7,859.71 | — | 7,706.27 | 6,700.22 | |
Beginning Cash |
26,290.86 | — | 25,775.54 | 17,846.79 | |
Ending Cash |
34,150.58 | — | 33,481.82 | 24,547.02 | |
Dividends Paid (Common) |
(5,442.03) | (5,442.03) | (5,747.25) | (5,442.03) | |
Assets Liabilities Change (Total) |
(2,528.40) | — | (143.58) | — | |
Investments Change (Net) |
(17,478.35) | — | (16,990.54) | — | |
Issuance/Purchase of Shares |
(10,429.02) | — | (11,278.65) | — |